{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-019186","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.408144+00:00","generated_at":"2026-06-14T13:12:05.041281+00:00","sec_items":["2.02","3.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Shuttle Pharmaceuticals Regains Nasdaq Compliance After Late Filing, Provides Pipeline Update","bullets":["Received delisting notice from Nasdaq on May 24 for failure to timely file Form 10-Q, but filed on May 25 and regained compliance.","Closed private placement of $4.3M secured convertible note and warrants for $4.0M investment.","Expects final submission to FDA for Phase II trial of Ropidoxuridine in glioblastoma by end of Q2 2023.","Awarded U.S. Patent No. 11,654,157 for cancer therapies combining halogenated thymidines and thymidine phosphorylase inhibitors with radiation.","Appointed Dr. Bette Jacobs as independent director to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-019186","json":"https://secwatch.observer/filing/0001493152-23-019186.json","markdown":"https://secwatch.observer/filing/0001493152-23-019186.md","text":"https://secwatch.observer/filing/0001493152-23-019186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/0001493152-23-019186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T13:12:05.041281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43e8542771666e76c9dab943040ea919e140de8b","claim":"Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 12B-25).","evidence_excerpt":"May 24, 2023, the Company received notice from the Nasdaq Stock Market, LLC (“Nasdaq”) that we have fallen out of compliance with the Nasdaq Listing Rules for continued listing as a result of being unable to file our Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Form 10-Q”) within the five day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. Our Form 10-Q had not been timely filed as a result of certain accounting complexities that arose in relation to our convertible note held by Alto Opportunity Master Fund, SPC – Segregated M","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/0001493152-23-019186-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"12B-25"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}